With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...
On Monday, Amneal Pharmaceuticals Inc (AMRX) stock saw a modest uptick, ending the day at $8.32 which represents a slight increase of $0.13 or 1.59% from the prior close of $8.19. The stock opened at ...
The race to supply obesity drugs is so competitive that one early-stage startup is already striking a deal for commercial ...
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global pharmaceutical company, and Metsera, Inc. ("Metsera"), a clinical-stage biopharmaceutical company accelerating the ...
Amneal Pharmaceuticals (AMRX) and Metsera have entered into a collaboration agreement to enable the efficient development and ...
Amneal Pharmaceuticals has sued Colorado in an effort to block a state law requiring it to provide free generic EpiPens to ...
Zacks.com on MSN27d
Amneal Stock Rises 29% in a Month on Upbeat Regulatory UpdatesAmneal Gets FDA Nod for Parkinson’s Disease Drug In August 2024, the FDA approved Amneal’s IPX203, a novel, oral formulation ...
Comprehensive access and affordability services to be made available to Parkinson’s patients and healthcare providers Amneal to hold CREXONT launch symposium and scientific presentations at the ...
A pharmaceutical corporation sued Colorado Friday in federal court aiming to bring a halt to a law approved in 2023, which ...
Amneal Pharmaceuticals Inc (AMRX) stock saw a decline, ending the day at $8.52 which represents a decrease of $-0.18 or -2.07% from the prior close of $8.7. The stock opened at $8.67 and touched a low ...
View Amneal Pharmaceuticals, Inc. (AMRX) current and estimated P/E ratio data provided by Seeking Alpha.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback